Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.

Baker, Ben; Bermingham, Imogen M; Leelasena, Indika; Hickling, Julian; Young, Paul R; Muller, David A; Forster, Angus H

Baker, Ben; Bermingham, Imogen M; Leelasena, Indika; Hickling, Julian; Young, Paul R; Muller, David A; Forster, Angus H.

Afiliación

Baker B; Vaxxas Pty Ltd., Hamilton, QLD 4007, Australia.
Bermingham IM; Vaxxas Pty Ltd., Hamilton, QLD 4007, Australia.
Leelasena I; University of the Sunshine Coast Clinical Trials Centre, Sippy Downs, QLD 4556, Australia.
Hickling J; Working in Tandem Ltd., Cambridge CB1 7AB, UK.
Young PR; School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD 4072, Australia.
Muller DA; School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD 4072, Australia.
Forster AH; Vaxxas Pty Ltd., Hamilton, QLD 4007, Australia.

Vaccines (Basel) ; 11(11)2023 Nov 17.

Article en En | MEDLINE | ID: mdl-38006057

Palabras clave

Phase I; clinical trial; high-density microarray patch (HD-MAP); measles (M); microarray patch (MAP); rubella (R); thermostability; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Australia